Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957.

Published: 18th July 2019

Authors: Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al.


A total of 716 patients were included. The docetaxel-based regimen improved median overall survival from 35 to 50 months (hazard ratio 0.77, 95 per cent confidence interval 0.63 to 0.94). Serious adverse event rates were similar.

Pubmed Link

Your comments